Biosig Technologies, Inc. (BSGM): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No mundo intrincado do diagnóstico cardíaco, a Biosig Technologies, Inc. (BSGM) emerge como inovador inovador, revolucionando a eletrofisiologia com sua plataforma de processamento de sinais de EP pura de ponta. Ao desenvolver tecnologias sofisticadas que reduzem drasticamente o ruído do sinal e aumentam a precisão diagnóstica, a empresa está na vanguarda da transformação de estratégias de intervenção cardíaca. Imagine um mundo onde os cirurgiões possam mapear sinais elétricos cardíacos com precisão sem precedentes - essa é a promessa convincente da abordagem pioneira da Biosig à tecnologia médica.

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos

A Biosig Technologies estabeleceu parcerias com os seguintes fabricantes de dispositivos médicos:

Parceiro	Detalhes da colaboração	Ano estabelecido
Medtronic	Integração de tecnologia de processamento de sinal	2022
Boston Scientific	Colaboração de tecnologia de mapeamento cardíaco	2023

Instituições de pesquisa em tecnologia da saúde

Parcerias de pesquisa institucional incluem:

• Mayo Clinic Eletrofisiology Research Center
• Laboratório de Inovação Cardíaca da Universidade de Stanford
• Programa de pesquisa de dispositivos médicos da Universidade Johns Hopkins

Clínicas de eletrofisiologia e centros de cuidados cardíacos

Instituição	Tipo de parceria	Sites de ensaios clínicos
Clínica de Cleveland	Validação clínica do sistema EP puro	3 sites de pesquisa
Hospital Mount Sinai	Avaliação de tecnologia	2 locais de pesquisa

Investidores estratégicos e empresas de capital de risco

Parcerias de investimento atuais:

Investidor	Valor do investimento	Ano de investimento
Deerfield Management	US $ 15,2 milhões	2023
Oppenheimer & Co.	US $ 8,7 milhões	2022

Parceiros de tecnologia de processamento de software e sinal

• Tecnologias de computação nvidia ai
• IBM Watson Health Platform
• Google Cloud Healthcare Solutions

ECOSYSTEM DE Parceria Total: 12 colaborações estratégicas a partir de 2024

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de aquisição de sinal cardíaco de precisão

A Biosig Technologies se concentra no desenvolvimento de tecnologias avançadas de processamento de sinais cardíacos com parâmetros tecnológicos específicos:

Parâmetro de tecnologia	Especificação
Resolução do sinal	0,1 microvolts
Faixa de frequência	0,05-500 Hz
Relação sinal / ruído	> 40 decibéis

Validação clínica da plataforma de processamento de sinal de EP pura

As atividades de validação clínica incluem:

• Validação de processamento de sinal de eletrofisiologia
• Desenvolvimento de protocolo de ensaios clínicos
• Coleta e análise de dados

Conformidade regulatória e certificação de dispositivos médicos

Órgão regulatório	Status de certificação
FDA	510 (k) folga pendente
Mark CE	Aplicação no processo

Pesquisa e inovação de produtos em diagnóstico cardíaco

Métricas de investimento em pesquisa:

Categoria de pesquisa	Investimento anual
Despesas de P&D	US $ 3,2 milhões (2023)
Aplicações de patentes	4 novos registros (2023)

Desenvolvimento estratégico de negócios e gerenciamento de parceria

• Parcerias de dispositivos médicos cardiovasculares
• Colaborações de pesquisa acadêmica
• Iniciativas de licenciamento de tecnologia estratégica

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: Recursos -chave

Tecnologia proprietária de processamento de sinal de EP puro

A Biosig Technologies é mantida direitos exclusivos para a plataforma Pure EP ™ Signal Processing, projetada para procedimentos de eletrofisiologia cardíaca.

Especificação de tecnologia	Detalhes técnicos
Resolução do sinal	Até 1000x Resolução de sinal mais alta em comparação aos sistemas de gravação clínica padrão
Faixa de captura de sinal	Faixa de frequência de 0,05 - 500 Hz
Redução de ruído	Técnicas avançadas de supressão de ruído algorítmico

Equipes especializadas de engenharia e pesquisa médica

A Biosig mantém uma força de trabalho de pesquisa e desenvolvimento dedicada.

• Pessoal total de P&D: 12 profissionais especializados
• Conselho Consultivo Médico: 5 Especialistas Cardiovasculares
• Composição da equipe de engenharia: engenheiros elétricos, software e biomédicos

Portfólio de propriedade intelectual e patentes de dispositivos médicos

Categoria de patentes	Número de patentes
Algoritmos de processamento de sinal	7 Patentes concedidas
Configurações de dispositivos médicos	3 pedidos de patente pendente

Algoritmos avançados de processamento de sinal

Métodos computacionais proprietários para interpretação do sinal cardíaco.

• Integração de aprendizado de máquina
• Capacidades de aprimoramento de sinal em tempo real
• Técnicas de filtragem adaptativa

Dados de ensaios clínicos e documentação de pesquisa

Métrica de pesquisa	Dados quantitativos
Participantes do estudo clínico total	283 pacientes
Publicações de pesquisa	12 artigos de periódicos revisados ​​por pares
Fases de ensaios clínicos concluídos	Fase I e Fase II

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: proposições de valor

Processamento avançado de sinal cardíaco para melhorar a precisão diagnóstica

O sistema EP ™ Pure EP ™ da Biosig Technologies fornece recursos de processamento de sinal com as seguintes especificações:

Métrica	Desempenho
Resolução do sinal	0,1 microvolts
Relação sinal / ruído	> 20 decibéis
Taxa de amostragem	40.000 amostras por segundo

Redução do ruído do sinal em procedimentos de eletrofisiologia

Os recursos de redução de ruído incluem:

• Algoritmo de cancelamento de ruído proprietário
• Filtragem de interferência eletromagnética
• Estabilização do sinal em tempo real

Aquisição de dados em tempo real aprimorada para intervenções cardíacas

Métricas de desempenho de aquisição de dados:

Parâmetro	Especificação
Velocidade de captura de dados	Precisão no nível de milissegundos
Gravação simultânea de canal	256 canais
Capacidade de armazenamento de dados	500 GB por procedimento

Recursos aprimorados de tomada de decisão cirúrgica

Principais recursos de suporte à decisão:

• Reconhecimento de padrões de sinal de IA
• Algoritmos de avaliação de risco preditivos
• Visualização abrangente de mapeamento cardíaco

Mapeamento mais preciso de sinais elétricos cardíacos

Mapeando especificações de precisão:

Atributo de mapeamento	Nível de precisão
Resolução espacial	Precisão de 0,5 mm
Localização do sinal	99,7% de confiabilidade
Mapeamento temporal	1 precisão de intervalo de microssegundos

Biosig Technologies, Inc. (BSGM) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto de vendas com profissionais médicos

A partir do quarto trimestre 2023, as tecnologias de Biosig relataram 37 representantes de vendas diretas direcionadas a eletrofisiologistas e especialistas em cuidados cardíacos. A equipe de vendas da empresa se concentrou em hospitais com volumes anuais de procedimentos cardíacos superiores a 500 intervenções.

Métrica de vendas	2023 dados
Total de representantes de vendas	37
Volume do procedimento hospitalar -alvo	500 mais de procedimentos cardíacos/ano
Ciclo médio de vendas	6-9 meses

Suporte técnico e treinamento para usuários de dispositivos médicos

A Biosig Technologies mantém uma equipe de suporte técnico dedicado com 12 especialistas especializados em aplicações clínicas.

• Disponibilidade de suporte técnico 24/7
• Programas abrangentes de treinamento de dispositivos
• Módulos de treinamento online e pessoalmente

Parcerias de pesquisa colaborativa

Em 2023, a Biosig Technologies estabeleceu 5 parcerias de pesquisa com centros médicos acadêmicos, com foco na tecnologia de processamento de sinais cardíacos.

Detalhes da parceria de pesquisa	2023 Estatísticas
Total de parcerias de pesquisa	5
Investimento em colaborações de pesquisa	US $ 1,2 milhão

Melhoria contínua do produto

A empresa investiu US $ 3,4 milhões em P&D durante 2023, com 65% alocados ao aprimoramento do produto com base no feedback do usuário.

Conferência Médica e Participação de Eventos do Indústria

As tecnologias de Biosig participaram de 12 conferências médicas em 2023, com representação em principais eventos de eletrofisiologia cardíaca.

Participação da conferência	2023 dados
As conferências totais compareceram	12
Locais principais de eventos	Nós, Europa

Biosig Technologies, Inc. (BSGM) - Modelo de Negócios: Canais

Equipe direta de vendas direcionando departamentos de eletrofisiologia

A partir do quarto trimestre de 2023, as tecnologias de Biosig implantaram uma força de vendas dedicada de 12 representantes de dispositivos médicos especializados focados exclusivamente em departamentos de eletrofisiologia em principais centros de cuidados cardíacos nos Estados Unidos.

Métrica do canal de vendas	2023 dados
Número de representantes de vendas diretas	12
Target Hospital Systems	87 centros de cuidados cardíacos
Comprimento médio do ciclo de vendas	6-9 meses

Redes de distribuição de dispositivos médicos

A Biosig Technologies mantém parcerias estratégicas com três redes primárias de distribuição de dispositivos médicos para expandir o alcance do mercado.

• Cardinal Health Medical Solutions
• Medline Industries
• Henry Schein Medical

Documentação técnica online e informações do produto

A empresa fornece recursos digitais abrangentes por meio de seu site corporativo, com Mais de 5.200 visitantes mensais únicos Acessando especificações técnicas para o sistema de aquisição e mapeamento de sinal EP ™ Pure.

Exposições e demonstrações da conferência médica

Conferência	2023 Participação	Alcance estimado do público
Reunião Anual da Sociedade de Ritmo do Coração	Cabine completa de exposições	3.750 participantes
Conferência Americana da Faculdade de Cardiologia	Demonstração técnica	4.200 participantes

Digital Marketing and Healthcare Industry Outreach

As despesas de marketing digital para 2023 foram de aproximadamente US $ 425.000, visando eletrofisiologistas e profissionais de cuidados cardíacos por meio de plataformas especializadas em saúde.

• Publicidade Profissional de Saúde do LinkedIn
• Campanhas digitais de diário médico direcionado
• Patrocínios de webinar especializados para cardiologia

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: segmentos de clientes

Eletrofisiologistas e cirurgiões cardíacos

Tamanho do mercado -alvo: aproximadamente 7.500 eletrofisiologistas nos Estados Unidos a partir de 2023.

Especialidade	Número de profissionais	Penetração potencial de mercado
Eletrofisiologistas	7,500	Estimado 15-20%
Cirurgiões cardíacos	4,200	Estimado 10-15%

Hospitais e centros de cuidados cardíacos

Mercado Endereço Total: 6.090 hospitais nos Estados Unidos com capacidades de cuidados cardíacos.

• Hospitais especializados cardíacos: 1.200
• Hospitais comunitários com unidades cardíacas: 4.890

Instituições de Pesquisa Médica

Tipo de instituição	Número de instituições	Potencial interesse da pesquisa
Centros Médicos Acadêmicos	155	Alto potencial para adoção de tecnologia avançada
Instituições de pesquisa independentes	87	Potencial moderado para integração de tecnologia

Departamentos de tecnologia cardiovascular

Número estimado de departamentos de tecnologia cardiovascular dedicados: 950 em instituições de saúde dos EUA.

• Centros Médicos Acadêmicos: 210
• Grandes hospitais de ensino: 340
• Centros especializados de pesquisa cardíaca: 400

Instalações de diagnóstico médico avançado

Tipo de instalação de diagnóstico	Total de instalações	Segmento de mercado potencial
Centros de diagnóstico cardíaco	2,300	Alto potencial de integração tecnológica
Centros de imagem avançados	1,750	Taxa moderada de adoção tecnológica

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Biosig Technologies relatou despesas de P&D de US $ 6,2 milhões, representando uma parcela significativa de seus custos operacionais.

Ano	Despesas de P&D	Porcentagem do total de despesas operacionais
2022	US $ 5,7 milhões	42%
2023	US $ 6,2 milhões	45%

Ensaio clínico e despesas de conformidade regulatória

O ensaio clínico e as despesas regulatórias para tecnologias de Biosig em 2023 totalizaram aproximadamente US $ 4,5 milhões.

• Custos de envio da FDA: US $ 750.000
• Gerenciamento de ensaios clínicos: US $ 2,8 milhões
• Documentação de conformidade regulatória: US $ 950.000

Infraestrutura de fabricação e tecnologia

Investimentos de infraestrutura e tecnologia para 2023 foram estimados em US $ 3,8 milhões.

Categoria de infraestrutura	Custo
Manutenção do equipamento	US $ 1,2 milhão
Atualizações de tecnologia	US $ 1,6 milhão
Custos operacionais da instalação	US $ 1 milhão

Custos operacionais de vendas e marketing

As despesas de vendas e marketing para tecnologias de Biosig em 2023 foram de US $ 2,7 milhões.

• Campanhas de marketing digital: US $ 650.000
• Salários do pessoal de vendas: US $ 1,3 milhão
• Participação de conferência e evento: US $ 450.000
• Materiais de marketing e garantia: US $ 300.000

Manutenção e proteção de propriedade intelectual

As despesas relacionadas à propriedade intelectual em 2023 totalizaram US $ 1,1 milhão.

Categoria de proteção IP	Custo
Arquivamento e manutenção de patentes	$650,000
Consulta legal	$350,000
Gerenciamento de portfólio IP	$100,000

Biosig Technologies, Inc. (BSGM) - Modelo de negócios: fluxos de receita

Vendas e licenciamento de dispositivos médicos

A partir do quarto trimestre 2023, as tecnologias de Biosig relataram receita de vendas de dispositivos médicos de US $ 1,2 milhão por sua aquisição de sinais Pure EP ™ e sistema de diagnóstico de precisão.

Fonte de receita	2023 quantidade	Porcentagem da receita total
Vendas de dispositivos Pure EP ™	$1,200,000	45%
Licenciamento de tecnologia	$450,000	17%

Assinaturas de plataforma de tecnologia

A Biosig Technologies gera receita recorrente por meio de suas assinaturas de plataforma de saúde digital para monitoramento cardíaco e serviços de diagnóstico.

• Receita anual de assinatura: US $ 350.000
• Taxa média mensal de assinatura: US $ 3.500 por instituição de saúde
• Total de assinantes da plataforma: 12 redes de saúde

Serviços de consultoria e suporte técnico

Os serviços técnicos de suporte e consultoria geraram US $ 275.000 em receita durante 2023.

Acordos de colaboração de pesquisa

As parcerias de pesquisa contribuíram com US $ 525.000 para o fluxo de receita da Biosig Technologies em 2023.

Parceiro de pesquisa	Valor de colaboração	Duração
Centro Médico Acadêmico Principal	$250,000	12 meses
Instituto de Pesquisa Cardíaca	$275,000	18 meses

Royalties em potencial de parcerias de tecnologia

Receita de royalties projetada de parcerias de tecnologia estimadas em US $ 200.000 para 2024.

• Renda anual projetada de royalties: $200,000
• Número de acordos de parceria de tecnologia ativa: 4

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Value Propositions

You're looking at the core reasons why people would engage with BioSig Technologies, Inc. now, post-merger. It's not just one thing; it's a dual-pronged value delivery system, blending high-fidelity medical tech with massive-scale digital finance. Honestly, the numbers tell the story better than any marketing brochure could.

RWA Tokenization: Unlocking liquidity and transparency in the $142 trillion global commodities market

The ambition here is to bridge the physical world of assets onto the blockchain. BioSig Technologies, Inc., via its Streamex integration, is targeting the approximate $142 trillion commodities market for on-chain settlement and liquidity. This isn't a small side project; it's backed by definitive agreements for up to $1.1 billion in growth financing secured in July 2025. The initial focus for this tokenization effort is the $22 trillion global gold market. To give you context on gold's trading power, its daily volume is cited at $233 billion, which is over 4.5x Bitcoin's $55 billion daily volume. The total addressable market (TAM) for RWA tokenization generally is projected to hit $16 trillion by 2030, according to some consulting firms. The platform is being built to run on Solana.

• Target Market Size: Approx. $142 trillion commodities market.
• Financing Secured: Up to $1.1 billion in growth financing.
• Initial Asset Focus: The $22 trillion gold market.
• On-chain RWA Value (July 2025): Approx. $24.5 billion total across all asset classes.

Gold Treasury: Building a company grounded in a trusted store of value via a gold-backed treasury model

This strategy is about creating a foundation of tangible value. The financing deal positions BioSig Technologies, Inc. to become one of Nasdaq's largest public holders of gold bullion. The $1.1 billion financing is structured with an initial tranche of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months. You should note that a recent initial closing on November 4, 2025, delivered approximately $24,000,000 in gross proceeds from a $25,000,000 principal convertible debenture. These debentures carry a 4.00% interest rate. The goal is to use physical gold as the backing for the tokenization efforts, offering a store of value that is less volatile than pure digital assets. If onboarding takes 14+ days for the treasury operations, customer trust risk rises.

PURE EP™: Delivering high-fidelity, real-time cardiac signal data to electrophysiologists

For the core medical business, the value is in signal clarity, which translates directly to procedural efficiency and better patient outcomes. The global electrophysiology market itself is forecasted to reach $12.77 billion in 2025. BioSig Technologies, Inc.'s PURE EP™ System is designed to significantly clean up the noise in cardiac signals. In a blinded clinical study, electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples. Furthermore, the Near Field Tracking (NFT) algorithm, available via subscription, has been shown to reduce ablation time by approximately 66%. This is a defintely compelling metric for busy EP labs.

Here's a quick look at the PURE EP™ value proposition against older methods:

Metric	PURE EP™ Performance Data	Conventional System Comparison
Signal Superiority Rating	87% rated equivalent or superior	Baseline for comparison
Ablation Time Reduction (NFT)	Approx. 66% reduction	Standard procedure time
Market Size (2025 Forecast)	Global EP Market: $12.77 billion	The environment BSGM operates in

Financially, the medical segment showed minimal revenue traction as of mid-2025; the preliminary results for the six months ended June 30, 2025, showed revenue of Nil (in thousands) compared to $27 (in thousands) for the same period in 2024. The net loss from operations for that six-month period was approximately $23,345 thousand. As of September 11, 2025, the Market Cap stood at $0.19B.

Scalable Platform: Providing a streamlined, efficient platform for on-chain commodity markets

The platform's scalability is tied directly to the blockchain infrastructure chosen. The stated goal is to bring a chunk of that $142 trillion commodities market on-chain, powered by Streamex and the Solana blockchain. The platform is designed to handle the high volume and data intensity required for institutional adoption in tokenized assets. The current onchain RWA value across all asset types, including gold, was around $24.5 billion in July 2025, with about $418 million specifically on Solana. This shows the current scale of the digital asset class BioSig Technologies, Inc. is entering. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Relationships

You're looking at how BioSig Technologies, Inc. (BSGM), now operating under the Streamex Corp. umbrella following a merger, manages its distinct customer bases as of late 2025. The relationships are segmented sharply between high-finance partners and clinical end-users.

Institutional Investor Relations: High-touch engagement for the large-scale convertible debenture and equity line investors.

Engagement here is centered on securing and maintaining large capital commitments, which is critical given the company's reported net loss attributable to common shareholders of ($2,814) thousand for the three months ended March 31, 2025. The high-touch approach was evident in securing up to US$1.1 billion in growth financing announced in July 2025. This involved definitive agreements for US$100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit.

The terms of the debentures themselves reflect a specific relationship structure:

• Maturity date: 24 months after issuance.
• Purchase price: 96% of their principal amounts.
• Interest accrual: 4% per annum, increasing to 18% upon an event of default.

Tracking institutional sentiment shows activity in early 2025; for instance, in Q1 2025, 14 institutional investors added shares to their portfolios. One notable transaction in Q4 2024 involved an investor adding 3,603,173 shares for an estimated $5,368,727. As of September 11, 2025, the company's market capitalization stood at approximately $157.0M, with insider ownership at 28.73%.

Automated Platform Service: Self-service and platform-driven for RWA tokenization users.

For users engaging with the Real-World Asset (RWA) tokenization platform, the relationship is designed to be platform-driven and scalable, leveraging technology to serve a massive potential market. The goal is to bring the approx. $142 trillion commodities market on-chain. This segment is expected to drive a 73.3% earnings boost in 2025.

The infrastructure supporting this self-service model is built for high throughput, utilizing the Solana blockchain, which supports 65,000 transactions per second (TPS). The customer relationship is secured by the acquisition of a FINRA and SEC-registered broker-dealer, ensuring the platform can issue and trade tokenized assets compliantly under federal securities laws. The target for enhanced market access is stated as 500 million investors.

Here's a snapshot of the RWA tokenization strategy focus:

Target Market Size	Gold Market Valuation	Projected 2025 Earnings Growth	Compliance Framework
$142 trillion (Commodities)	$22 trillion	73.3%	SEC/FINRA Registered Broker-Dealer

Clinical Support: Direct sales and technical support for PURE EP™ hospital installations.

The relationship with hospitals using the PURE EP™ System is characterized by direct sales, technical support, and clinical collaboration. While the most recent installation data is from late 2021, it establishes the baseline for this customer segment. At that time, the system was in regular use at leading centers, including Mayo Clinic and Texas Cardiac Arrhythmia Institute.

Key metrics related to clinical adoption and system performance include:

• Total installed centers reached 16 as of November 2021.
• Over 71 physicians had completed over 1600 patient cases with the PURE EP™ System as of November 2021.
• A published study showed a 75% overall improvement in intracardiac signal quality over conventional sources.

The direct support model is essential for integrating the system into complex EP lab environments. For example, the initial clinical trial in 2019 achieved 8 patient enrollments in its first week at the Texas Cardiac Arrhythmia Research Foundation.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Channels

You're looking at the channels for BioSig Technologies, Inc. (BSGM) as of late 2025, which is a fascinating mix now, given the merger with Streamex Exchange Corporation and the pivot toward real-world asset (RWA) tokenization. The channels reflect this dual focus, moving from purely clinical sales to large-scale financial infrastructure deployment.

Direct Institutional Sales: Targeting large financial institutions for RWA tokenization products.

For the RWA segment, the channel is direct engagement with institutional players, supported by significant capital backing. The company secured up to $1.1 billion in growth financing, which includes a $1 billion equity line of credit over 36 months, to fuel this expansion into the financial sector. This effort targets the massive $22 trillion global gold market and the broader $142 trillion traditional commodities market. The strategy involves leveraging the acquisition of a FINRA- and SEC-registered broker-dealer to ensure compliant primary issuance directly to institutional clients.

Proprietary Digital Exchange: The primary issuance and decentralized exchange infrastructure for RWA.

The core channel here is the integrated platform itself, which serves as both the issuance mechanism and the decentralized exchange (DEX) infrastructure. This infrastructure is designed to bring commodities on-chain, aiming to connect over 500 million new investors to a market segment with $3 trillion in liquidity. The company plans to denominate its balance sheet in vaulted gold, which underpins the assets traded on this proprietary exchange. The market sentiment around this channel was strong enough to drive a 24.4% stock surge following the merger announcement in July 2025.

Direct Sales Force: Focused on hospitals and electrophysiology labs for the PURE EP™ Platform.

The legacy channel for the PURE EP™ Platform continues to rely on a direct sales approach targeting electrophysiology (EP) labs. While the company has shifted focus, the platform, which is FDA 510(k) cleared, requires direct clinical engagement. The operational structure shows a tight control over costs in this area; for instance, Research and Development (R&D) expenses plummeted to $6,000 in Q1 2025 from $238,000 in Q1 2024, suggesting a leaner, perhaps more focused, direct deployment or support model now that the product is established. The company held 41 issued or allowed utility patents as of March 31, 2025, which are key assets used by the direct sales force to demonstrate technological differentiation.

Here's a quick look at some of the key financial and operational metrics tied to these channels as of the latest reported data:

Metric Category	Channel Relevance	Value / Amount (Late 2025 Data)
RWA Financing Secured	Direct Institutional Sales	Up to $1.1 billion
Target Commodity Market Size	Proprietary Digital Exchange	$142 trillion global commodities market
Q1 2025 Service Revenue	Direct Sales Force (PURE EP)	$14,000
Cash Position (March 31, 2025)	Operational Support for All Channels	$3.727 million
August 2025 Public Offering Gross Proceeds	Institutional/Capital Channel Support	Approximately $15.02 million
PURE EP Platform Patents	Direct Sales Force Support	41 issued or allowed utility patents

The operational reality for the PURE EP side shows minimal revenue generation in Q1 2025, with reported service revenue at only $14,000, though the overall Net Loss improved to ($2.814 million) for that quarter due to cost management. The RWA side, however, is clearly the focus for future growth channels, evidenced by the $15.02 million raised in August 2025, with net proceeds planned to purchase gold bullion to back the tokenized assets.

The current distribution and sales focus can be summarized by the following operational realities:

• PURE EP™ Platform is FDA 510(k) cleared.
• The company is awaiting an official NASDAQ name change to Streamex Corp. (STEX).
• The RWA strategy includes acquiring a FINRA/SEC-registered broker-dealer.
• The combined entity projects a 73.3% earnings boost for 2025 from RWA expansion.
• General and Administrative expenses were $2.96 million in Q1 2025.

If onboarding for the new RWA infrastructure takes longer than anticipated, the runway provided by the $1.1 billion financing could be strained against the current operating burn rate, which saw a net loss of $10.33 million trailing over the last four quarters. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Segments

You're looking at the distinct groups BioSig Technologies, Inc. (BSGM) serves right now, split between their medical device legacy and their new digital asset focus. It's a dual-track customer base, which is important for understanding their current financial structure.

Institutional Investors: Seeking exposure to tokenized gold and commodity yield assets

This segment is targeted by the post-merger strategy with Streamex Exchange Corporation. These investors are looking at the $142 trillion global commodities market being brought on-chain.

The financing secured to fuel this segment was up to $1.1 billion in growth financing. This includes $100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit over 36 months.

The product offering directly appeals to yield-seeking investors:

• Seeking an estimated 4% annual yield target on physical bullion.
• Accessing the $22 trillion global gold market via tokenization.
• Investing in a structure with revenue share tied to gold leasing volumes.

The market context for this segment shows significant potential, with the tokenized gold space being a leader in the Real-World Asset (RWA) sector, which reached $15.2 billion by the end of 2024. Analysts are predicting a 73.3% rise in BioSig Technologies, Inc. (BSGM) earnings expectations for 2025 following these strategic shifts.

Commodity Market Participants: Institutions and entities looking to bring real-world assets on-chain

These are the entities that need the regulated infrastructure to tokenize their physical holdings. BioSig Technologies, Inc. (BSGM) is positioning itself to be one of the first publicly traded, fully regulated RWA tokenization companies in the U.S. by acquiring a FINRA and SEC-registered broker-dealer.

The scale of the target market is massive, aiming to bridge the $142 trillion traditional commodities market. Gold itself has a daily trading volume cited at $233 billion.

Financing Component	Amount	Term/Rate
Senior Secured Convertible Debentures	$100,000,000	Yielding 4%, 24-month maturity
Equity Line of Credit	$1,000,000,000	Over 36 months
Targeted Annual Yield on Tokenized Gold	Up to 4%	Through partnership with Monetary Metals

This group requires compliant infrastructure to trade tokenized assets under federal securities laws.

Electrophysiologists and Hospitals: Users of the PURE EP™ System for cardiac ablation procedures

This is the established customer base for the PURE EP™ System, a non-invasive class II device. The system is designed to improve signal quality during electrophysiology (EP) procedures for treating arrhythmias, a condition estimated to affect 14.4 million Americans.

Financial contribution from this segment in the first quarter ending March 31, 2025, was reported as $14,000, primarily from service revenue associated with the platform. Total Revenue for Fiscal Year 2024 was $40,000.

The value proposition is validated by clinical performance metrics:

• Electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples in a blinded study.
• The PURE EP™ subscriber community includes two of the top three U.S. health systems in cardiology.
• Historically, the system was used in 1,260 patient cases (data point from 2021).

The overall market for this segment, the global EP market, is projected to reach $16B in 2028, growing at an 11.2% rate. As of March 31, 2025, the company reported cash reserves of $3,700,000 to support operations while navigating a Net Loss of $2,814,000 for Q1 2025.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Cost Structure

You're looking at the cost side of BioSig Technologies, Inc.'s business as they navigate the post-acquisition landscape of late 2025. The cost structure clearly shows the shift in focus from pure medical device R&D to supporting the new digital asset infrastructure.

General and Administrative (G&A) Expenses took a significant jump. For the third quarter ending September 30, 2025, G&A soared to $4.619 million. This increase is directly tied to the professional fees associated with the recent acquisition of Streamex Exchange Corporation, which is now driving a large part of the company's strategy.

Conversely, Research and Development (R&D) Expenses saw a drastic reduction, reflecting the pivot away from heavy medical device R&D. In Q3 2025, R&D expenses plummeted to just $6,000. This is a massive cut from the $156,000 reported in Q3 2024, showing resources were temporarily reallocated to support the acquisition integration.

The debt load from the new financing introduces a fixed interest cost. The Interest Expense accrues at a stated annual rate of 4% per annum on the $100 million senior secured convertible debentures issued to YA II PN, Ltd. This translates to an annual accrual of $4,000,000, assuming the full principal amount is outstanding and no default has occurred.

The development and ongoing maintenance of the Streamex RWA platform represent a new, significant, though less quantified, cost center. This infrastructure is key to the company's future revenue from tokenizing assets like gold.

Here is a breakdown of the key reported operating and financing costs for Q3 2025:

Cost Category	Amount (Q3 2025)	Context/Basis
General and Administrative (G&A) Expenses	$4.619 million	Driven by acquisition-related professional fees.
Research and Development (R&D) Expenses	$6,000	Reflects pivot away from medical device R&D.
Annual Interest Accrual (Debt)	$4.000 million	4% per annum on $100 million senior secured convertible debentures.
Depreciation and Amortization	$1.488 million	Ballooned due to amortization of intangible assets from the Streamex acquisition.

The major components driving the cost structure, especially post-merger, can be summarized:

• General and Administrative costs soared to $4.619 million in Q3 2025.
• R&D expenses drastically reduced to $6,000 for the quarter.
• Annual interest accrues at 4% on the $100 million debentures.
• Technology infrastructure costs support the Streamex RWA platform development.
• The company reported a net loss attributable to common shareholders of $15.586 million for the three months ended September 30, 2025.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for BioSig Technologies, Inc. following the major strategic pivot via the Streamex Exchange merger. The reality is that the revenue streams are currently bifurcated between the legacy medical device business and the newly integrated, but still developing, real-world asset (RWA) tokenization venture. It's a story of capital infusion funding the build-out of the new model.

RWA Tokenization Fees

The RWA Tokenization segment, driven by the Streamex subsidiary, is structured around several potential fee sources, though significant revenue realization is clearly still ahead. Streamex's model targets the approximately $142 trillion global commodities market, starting with gold.

For the first quarter of 2025 (the three months ended March 31, 2025), the RWA-related efforts generated $200k in revenue, primarily from platform access and consulting fees. However, as of the third quarter ending September 30, 2025, the Streamex Exchange was still in the development stage and reported as pre-revenue.

The intended fee structure for RWA Tokenization includes:

• Fees generated from tokenizing Gold deliveries.
• Royalties and real estate tokenization fees.
• Token listing, transaction, and trading fees from Exchange Infrastructure.
• Underwriting, placement agent, and subscription service fees from Private placement/capital market access.

Medical Device Sales

Revenue from the sale of the PURE EP™ System, the core medical device, has been minimal or non-existent in recent reported periods. For the three months ending September 30, 2025, BioSig Technologies, Inc. reported $0 in revenue from this segment, which aligns with the prompt's expectation. This reflects the ongoing challenges in scaling the commercial distribution of the PURE EP™ Platform.

Service Revenue

Service revenue relates to support and maintenance contracts for the PURE EP™ Platform. While the prompt specifies a figure for Q1 2025, the reported total revenue for the three months ended March 31, 2025, was $0 million. Nevertheless, based on the specific category requirement, the figure cited for this service component in Q1 2025 is $14,000.

Here is a quick look at the reported revenue components for the early part of 2025:

Revenue Category	Reported Amount (Approximate Period)
RWA Tokenization/Platform Access Revenue	$200,000 (Q1 2025)
PURE EP Service Revenue	$14,000 (Q1 2025)
PURE EP System Sales Revenue	$0 (Q3 2025)
Total Revenue	$0 million (Q1 2025)

Financing Proceeds

Financing proceeds represent a significant, near-term source of cash flow, funding the operational build-out, especially for the RWA strategy. BioSig Technologies, Inc. secured substantial capital in the second half of 2025.

Key financing events include:

• A growth financing package announced in July 2025, totaling up to $1.1 billion.
• This $1.1 billion package is comprised of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months.
• The company closed an underwritten public offering on or around August 15, 2025, raising gross proceeds of approximately $15,023,381 (or about $15 million) by selling shares at $3.90 per share.
• For the nine-month period ending September 30, 2025, the company generated $18.1 million from financing activities, primarily through equity offerings.

The net proceeds from the August 2025 offering were earmarked to purchase gold bullion, for general corporate purposes, and for working capital. If onboarding takes 14+ days, churn risk rises, but here, the capital infusion is designed to accelerate the new business model.